Postavení aripiprazolu v klinické praxi
| Title in English | Position of aripiprazole in clinical practice |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská psychiatrie |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | aripiprazole; efficacy; tolerability; schizofrenic disorder; affective disorder; monotherapy; augmentation |
| Description | Data about efficacy of aripiprazole in the treatment of schizophrenic and bipolar disorder are summarized. In schizophrenia aripiprazole represents a common strategy in patients with sedation and weight increase on the present treatment. In bipolar disorder aripiprazole belongs to antipsychotics of the second generation influencing mostly the manic component of the disorder. Undoubtedly it is iteresting, that aripiprazole like others antipsychotics represents a successful augmentation in pharmacoresistant depression. An advantage is the different profile of adverse events. Aripiprazole is minimally associated with weight increase and metabolic adverse events. It represents a justified enlargement of possibilities of individualized treatment, which is considered to be an optimal strategy in the treatment of severe psychic disorders. |
| Related projects: |